LIPT1 and non-small cell lung carcinoma: To validate the results from the CRISPR screen, we established stable LIPT1 knockout (LIPT1−/−) and nontargeting control wild-type (WT) NSCLC H460 and H157 cells using CRISPR-Cas9.